Matches in Wikidata for { <http://www.wikidata.org/entity/Q90359416> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q90359416 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90359416 description "scientific article published on 01 June 2018" @default.
- Q90359416 description "wetenschappelijk artikel" @default.
- Q90359416 description "наукова стаття, опублікована в червні 2018" @default.
- Q90359416 name "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 name "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 type Item @default.
- Q90359416 label "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 label "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 prefLabel "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 prefLabel "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 P1433 Q90359416-10813F5B-2B36-4D7D-B6B1-2FA09B7D854F @default.
- Q90359416 P1476 Q90359416-8BE5136D-DD47-4967-A367-CE47B690F5AC @default.
- Q90359416 P2093 Q90359416-47D90680-2677-4585-80E2-9FF267EB5CA2 @default.
- Q90359416 P2093 Q90359416-7099DC86-5610-4AE8-953B-A3400A7AD74C @default.
- Q90359416 P2093 Q90359416-8D4C865A-3F46-4138-800E-56F105CC2C65 @default.
- Q90359416 P2093 Q90359416-C46D5100-B3C1-4FC5-8006-61649973D299 @default.
- Q90359416 P304 Q90359416-BDD4EAD3-A8BD-4919-A9FE-5ECC2E25729E @default.
- Q90359416 P31 Q90359416-394BB833-6807-466C-BDD5-27FF778B6C6F @default.
- Q90359416 P356 Q90359416-6AD5E5FB-27CB-4C08-935D-889153D05D43 @default.
- Q90359416 P478 Q90359416-CDA90FC0-124B-42A5-BD8F-497A7E5F1E5A @default.
- Q90359416 P577 Q90359416-032CA55C-BCED-4553-A792-E282DD5174C2 @default.
- Q90359416 P921 Q90359416-1AECEDB2-2E53-46A5-85D9-28949D854678 @default.
- Q90359416 P921 Q90359416-5D55986C-4534-435E-AA61-EC18E40BAC99 @default.
- Q90359416 P921 Q90359416-D9626E6D-3A9D-4B52-AC62-02E75E0205E0 @default.
- Q90359416 P356 MDY151.229 @default.
- Q90359416 P1433 Q326122 @default.
- Q90359416 P1476 "Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors" @default.
- Q90359416 P2093 "M Chmielowiec" @default.
- Q90359416 P2093 "M Gryziak" @default.
- Q90359416 P2093 "R Biernacka" @default.
- Q90359416 P2093 "T Lewandowski" @default.
- Q90359416 P304 "v64-v65" @default.
- Q90359416 P31 Q13442814 @default.
- Q90359416 P356 "10.1093/ANNONC/MDY151.229" @default.
- Q90359416 P478 "29 Suppl 5" @default.
- Q90359416 P577 "2018-06-01T00:00:00Z" @default.
- Q90359416 P921 Q108566365 @default.
- Q90359416 P921 Q188874 @default.
- Q90359416 P921 Q413299 @default.